Trial intelligence / Profile preview

Phase II single-arm study of alectinib after progression on prior ALK inhibitor therapy in ALK-rearranged NSCLC

2016-003924-22Phase 2Completed

Sponsor

Roche

Start

Mar 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1